Authors : Nageshwar Sharma, Nageshwar Sharma, Jayshree Kedia, Jayshree Kedia
DOI : 10.18231/j.ijceo.2019.074
Volume : 5
Issue : 3
Year : 2019
Page No : 310-313
The study was conducted to ascertain the efficacy and safety of topical bepotastine besilate solution (BBOS) 1.5% in controlling allergic conjunctivitis. The study design was randomized and out-patient department (OPD) based. Total 50 patients were included. They had symptoms and signs of allergic conjunctivitis. Symptoms included ocular itching, conjunctival redness, watering running nose, lacrimation, photophobia and foreign body sensation and signs included papillae, follicles, chemosis, hyperaemia and cobblestones. The data was gathered together after detailed history taking. We recorded baseline symptoms score(BSS) of each patient who fulfilled the inclusion and exclusion criteria. After that we started topical BBOS 1.5% one drop twice daily for 21 days and advised patients to immediately stop the drug and review in OPD in case of any aggravation of symptoms or burning sensation.
We examined patients on each follow up day 7, day 14 and day 21 by slit lamp biomicroscopy and recorded total mean symptoms and signs. Symptoms of allergic conjunctivitis especially ocular itching subsided within 7 days of the treatment, while other significant signs and symptoms subsided within 14 days of treatment. The interesting fact was observed that on 21st day of follow up cobblestones were flattened.
To conclude the use of bepotastin besilate 1.5% topically leads to an improvement in sign and symptoms in a significant number of patients. No significant side effects were noticed and patient compliance has been encouraging.
We recommended the use of BBOS 1.5% eye drop in all patents of mild to moderate allergic conjunctivitis.
Keywords: Allergic conjunctivitis, Bepotastine besilate ophthalmic solution (BBOS), Cobblestones, Itching, Redness.